Axsome Therapeutics, Inc. (AXSM)

NASDAQ: AXSM · Real-Time Price · USD
118.64
-1.30 (-1.08%)
Oct 7, 2025, 4:00 PM EDT - Market closed
-1.08%
Market Cap5.92B
Revenue (ttm)495.03M
Net Income (ttm)-246.90M
Shares Out 49.90M
EPS (ttm)-5.06
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume402,305
Open119.81
Previous Close119.94
Day's Range117.50 - 120.79
52-Week Range75.56 - 139.13
Beta0.51
AnalystsStrong Buy
Price Target174.26 (+46.88%)
Earnings DateNov 3, 2025

About AXSM

Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Nov 19, 2015
Employees 683
Stock Exchange NASDAQ
Ticker Symbol AXSM
Full Company Profile

Financial Performance

In 2024, Axsome Therapeutics's revenue was $385.69 million, an increase of 42.53% compared to the previous year's $270.60 million. Losses were -$287.22 million, 20.1% more than in 2023.

Financial Statements

Analyst Summary

According to 19 analysts, the average rating for AXSM stock is "Strong Buy." The 12-month stock price target is $174.26, which is an increase of 46.88% from the latest price.

Price Target
$174.26
(46.88% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

1 day ago - GlobeNewsWire

Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit September 17, 2025 8:40 AM EDT Company Participants Mark Jacobson - Chief Operating...

20 days ago - Seeking Alpha

Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025

Six poster presentations showcase clinical and real-world data in major depressive disorder, Alzheimer's disease agitation, narcolepsy, and obstructive sleep apnea Six poster presentations showcase cl...

21 days ago - GlobeNewsWire

Axsome Therapeutics, Inc. (AXSM) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 2:35 PM EDT Company Participants Mark Jacobson - Chief Operating Officer Nick Pizzie ...

4 weeks ago - Seeking Alpha

Axsome Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

6 weeks ago - GlobeNewsWire

Axsome Therapeutics Analysts Increase Their Forecasts After Q2 Earnings

Axsome Therapeutics, Inc. AXSM reported better-than-expected second-quarter financial results on Monday.

2 months ago - Benzinga

Axsome Therapeutics, Inc. (AXSM) Q2 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q2 2025 Earnings Conference Call August 4, 2025 8:00 AM ET Company Participants Ari Maizel - Chief Commercial Officer Darren Opland - Corporate Participant Her...

2 months ago - Seeking Alpha

Axsome Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Total 2Q 2025 net product revenue of $150.0 million, representing growth of 72% year-over-year and 24% sequentially AUVELITY ® 2Q 2025 net product sales of $119.6 million, representing growth of 84% y...

2 months ago - GlobeNewsWire

Axsome: Some Recent Setbacks, Some Recent Wins -- Still A Buy

Axsome's valuation is driven by its promising pipeline, with Auvelity as a proven commercial success and Symbravo and AXS-12 showing solid potential. Recent setbacks include the FDA's refusal to file ...

2 months ago - Seeking Alpha

Axsome Therapeutics Hosts Frontiers in Brain Health R&D Day Reviewing Industry-Leading Late-Stage CNS Pipeline

Comprehensive review of broad pipeline targeting Alzheimer's disease agitation, depression, narcolepsy, fibromyalgia, ADHD, and smoking cessation, with new data analyses

2 months ago - GlobeNewsWire

Axsome Therapeutics to Report Second Quarter 2025 Financial Results on August 4

NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

3 months ago - GlobeNewsWire

Axsome Therapeutics to Showcase Its Innovative CNS Pipeline at Upcoming Frontiers in Brain Health R&D Day in New York City on July 21

NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

3 months ago - GlobeNewsWire

Axsome Therapeutics Champions Brain Health During Alzheimer's & Brain Awareness Month

NEW YORK, June 20, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today is...

3 months ago - GlobeNewsWire

Axsome Therapeutics Showcases Innovation in Sleep Medicine with Multiple Presentations for AXS-12 and Solriamfetol at SLEEP 2025

NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...

4 months ago - GlobeNewsWire

Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Hetero Labs Ltd.

NEW YORK, May 27, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, ...

4 months ago - GlobeNewsWire

Axsome Therapeutics Enters $570 Million Term Loan and Revolving Credit Facility with Blackstone

Previous term loan facility retired NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervo...

5 months ago - GlobeNewsWire

Axsome Therapeutics Q1: Marketing-Driven Growth Masks Profitability Concerns

Axsome Therapeutics reported strong Q1 2025 earnings, with revenue and EPS beats driven by Auvelity and Sunosi, despite high SG&A expenses and net loss. Auvelity shows promising growth in the competit...

5 months ago - Seeking Alpha

Axsome Therapeutics, Inc. (AXSM) Q1 2025 Earnings Call Transcript

Axsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - CEO Nick Piz...

5 months ago - Seeking Alpha

Axsome Therapeutics Clocks Around 60% Topline Growth In Q1

Axsome Therapeutics Inc  AXSM on Monday reported first-quarter 2025 revenues of $121.5 million, up from $75 million a year ago, beating the consensus of $119.87 million.

5 months ago - Benzinga

Axsome Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Total 1Q 2025 net product revenue of $121.5 million, representing 62% year-over-year growth AUVELITY ® 1Q 2025 net product sales of $96.2 million, representing 80% year-over-year growth SUNOSI ® 1Q 20...

5 months ago - GlobeNewsWire

Axsome Therapeutics and Mental Health America (MHA) Join Voices to Highlight Mental Health Month

NEW YORK, May 01, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today ann...

5 months ago - GlobeNewsWire

Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5

NEW YORK, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today a...

6 months ago - GlobeNewsWire

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

Late-breaking oral presentation of results from the positive pivotal ACCORD-2 Phase 3 trial of AXS-05 in Alzheimer's disease agitation

6 months ago - GlobeNewsWire

Axsome's depression treatment fails to meet main goal of late-stage study

Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.

6 months ago - Reuters

Axsome Therapeutics' ADHD drug meets main goal in late-stage study

Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.

7 months ago - Reuters